What is NDC 45802-706?

45802-706 is the product NDC for Tazarotene, Tazarotene .5 mg/g cream, listed with the FDA by Padagis Israel Pharmaceuticals Ltd. It has 2 package NDCs, shown above in 10- and 11-digit form.

Padagis Israel Pharmaceuticals Ltd, NDC labeler code 45802. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.

What other NDCs exist for Tazarotene?

14 other product NDCs are listed under this name.

Is there a related HCPCS / J-code?

Not in Med-Code's curated HCPCS directory.

Tazarotene NDC 45802-706 | National Drug Code

NDC codes

FDA NDC Directory

Product NDC (as listed)45802-706Labeler and product segments. Claims need a package NDC.

Product NDC at billing width45802-0706Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
45802-706-94	4580207069445802070694	1 TUBE in 1 CARTON (45802-706-94) / 30 g in 1 TUBEMarketed from Sep 9, 2024
45802-706-96	4580207069645802070696	1 TUBE in 1 CARTON (45802-706-96) / 60 g in 1 TUBEMarketed from Sep 9, 2024

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Tazarotene
Generic name (nonproprietary): tazarotene
Active ingredients: Tazarotene — .5 mg/g
Dosage form: Cream
Route: Topical
Labeler: Padagis Israel Pharmaceuticals LtdNDC labeler code 45802
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 217075
Marketing start: Sep 9, 2024
Listing expires: Dec 31, 2026
Other FDA classes: Retinoids (Chemical structure)
Identifiers: Product ID 45802-706_27ddf7ba-f3a2-43ff-83a5-e7c95b355028SPL ID 27ddf7ba-f3a2-43ff-83a5-e7c95b355028SPL set ID df5d65de-0693-4fd2-b335-f04ab1e201e7RxCUI 314268UNII 81BDR9Y8PS
Pharmacologic class: Retinoid

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Topical products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N445802070694 followed by a unit qualifier and the quantity

Package 45802-0706-94. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective May 31, 2024.

Indications (excerpt from the label)

• Tazarotene cream, 0.05% is a retinoid indicated for the topical treatment of plaque psoriasis. ( 1.1 ) 1.1 Plaque Psoriasis Tazarotene cream, 0.05% is indicated for the topical treatment of patients with plaque psoriasis.

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

About NDC 45802-706

What is NDC 45802-706?: 45802-706 is the product NDC for Tazarotene, Tazarotene .5 mg/g cream, listed with the FDA by Padagis Israel Pharmaceuticals Ltd. It has 2 package NDCs, shown above in 10- and 11-digit form.
What drug is associated with this NDC?: Tazarotene.
What is the active ingredient?: Tazarotene.
Who is the labeler?: Padagis Israel Pharmaceuticals Ltd, NDC labeler code 45802. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.
What other NDCs exist for Tazarotene?: 14 other product NDCs are listed under this name. See all Tazarotene NDCs.
Is there a related HCPCS / J-code?: Not in Med-Code's curated HCPCS directory. See Billing references above.

Other finished products listed under the same name: strengths, forms and labelers.

Other Tazarotene NDCs
Product	Strength	Form · route	Labeler	Product NDC	Package NDCs (11-digit)
Tazarotene	Tazarotene .5 mg/g	CreamTopical	Cosette Pharmaceuticals, Inc.	0713-0765	00713-0765-3100713-0765-60
Tazarotene	Tazarotene .5 mg/g	GelCutaneous	Solaris Pharma Corporation	73473-309	73473-0309-1073473-0309-30
Tazarotene	Tazarotene 1 mg/g	GelCutaneous	Solaris Pharma Corporation	73473-310	73473-0310-1073473-0310-30
Tazarotene	Tazarotene .5 mg/g	CreamTopical	Bryant Ranch Prepack	72162-2420	72162-2420-0372162-2420-06
Tazarotene	Tazarotene .5 mg/g	GelTopical	Padagis Israel Pharmaceuticals Ltd	45802-436	45802-0436-0145802-0436-94
Tazarotene	Tazarotene 1 mg/g	GelTopical	Padagis Israel Pharmaceuticals Ltd	45802-442	45802-0442-0145802-0442-94
Tazarotene	Tazarotene 1 mg/g	GelTopical	Bryant Ranch Prepack	72162-2202	72162-2202-03
Tazarotene	Tazarotene 1 mg/g	GelTopical	Cosette Pharmaceuticals, Inc.	0713-0804	00713-0804-3100713-0804-99
Tazarotene	Tazarotene .5 mg/g	GelTopical	Cosette Pharmaceuticals, Inc.	0713-0805	00713-0805-3100713-0805-99
Tazarotene	Tazarotene 1 mg/g	CreamTopical	Mayne Pharma	68308-745	68308-0745-30

All 15 Tazarotene NDCs

Other NDCs under ANDA 217075

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 217075
Product	Strength	Form · route	Labeler	Product NDC
Tazarotene	Tazarotene .5 mg/g	CreamTopical	Bryant Ranch Prepack	72162-2420